Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
Eiichi ArakiShizuya YamashitaHidenori AraiKoutaro YokoteJo SatohToyoshi InoguchiJiro NakamuraHiroshi MaegawaNarihito YoshiokaYukio TanizawaHirotaka WatadaHideki SuganamiShun IshibashiPublished in: Diabetes care (2018)
Pemafibrate significantly ameliorated lipid abnormalities and was well tolerated in patients with type 2 diabetes comorbid with hypertriglyceridemia.